Anti-interleukin-13 antibodies, lebrikizumab, and tralokinumab are effective for atopic dermatitis (AD); however, real-world data on 1-year effectiveness for head and neck (H&N) lesions are limited. To evaluate the effectiveness of 48-week lebrikizumab or tralokinumab treatment on H&N lesions in patients with moderate-to-severe AD. We conducted a two-center retrospective study of Japanese AD patients treated with lebrikizumab (n = 160) or tralokinumab (n = 171). H&N eczema area and severity index (EASI) was assessed through 48 weeks in total patients or subgroups of baseline H&N EASI < 3 or ≥ 3. Lebrikizumab and tralokinumab rapidly reduced H&N EASI by Week 4, which was maintained through Week 48. At Week 48, achievement rates of H&N EASI 75, 90, or 100 were 77.3%, 37.3%, or 17.3% with lebrikizumab, and 75.0%, 44.8%, or 29.2% with tralokinumab, respectively. In lebrikizumab treatment, patients with baseline H&N EASI ≥ 3 showed numerically higher achievement rates of H&N EASI 90 at Week 16 and 48 compared to those with baseline H&N EASI < 3, whereas the results were the trend differed in tralokinumab treatment. This subgroup observation was limited to small baseline H&N EASI ≥ 3 subgroups and may not be generalizable. Taken together, treatment with lebrikizumab and tralokinumab rapidly reduced H&N EASI by Week 4, and these improvements were maintained through Week 48.
Keywords: IL‐13; atopic dermatitis; head and neck; lebrikizumab; tralokinumab.
© 2026 Japanese Dermatological Association.